Pearson Plaintiffs Using Shortened Omega-3 Qualified Claim
This article was originally published in The Tan Sheet
Executive Summary
Two of the Pearson plaintiffs plan to incorporate an abbreviated version of FDA's qualified health claim for omega-3 fatty acids and coronary heart disease on dietary supplement labeling.
You may also be interested in...
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge
FDA must draft "one or more appropriately short, succinct and accurate disclaimers" to accompany the Pearson plaintiffs' proposed dietary supplement health claim for folic acid/neural tube defects, a Washington, D.C. judge ruled Feb. 1 in a firmly worded opinion.
FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge
FDA must draft "one or more appropriately short, succinct and accurate disclaimers" to accompany the Pearson plaintiffs' proposed dietary supplement health claim for folic acid/neural tube defects, a Washington, D.C. judge ruled Feb. 1 in a firmly worded opinion.